<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia
Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate $(ADC)$, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。